Drug transporters in chemotherapy induced peripheral neurotoxicity: Current knowledge and clinical implications

Current Medicinal Chemistry

Volumn 18, Issue 3, 2011, Pages 329-341

  Ceresa, C ^a   Cavaletti, G ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Cemotherapy induced neurotoxicity; Dorsal root ganglia; Transporter; Uptake

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BISANTRENE; BORTEZOMIB; CISPLATIN; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IRINOTECAN; MENKES PROTEIN; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; PACLITAXEL; TENIPOSIDE; THALIDOMIDE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; WILSON DISEASE PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CHEMOTHERAPY; GENOTYPE; HUMAN; KNOWLEDGE; NEUROTOXICITY; NONHUMAN; OVARY CANCER; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL GANGLION;

EID: 79251515147     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794839160     Document Type: Article

References (133)

1. Schinkel, A.H.; Jonker, J.W.; Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv. Drug Deliv. Rev., 2003, 55, 3-29.
2. Yonezawa A.; Masuda, S.; Nishihara, K.; Yano, I.; Katsura, T.; Inui, K.; Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem. Pharmacol., 2005, 70, 1823-1831.
3. Yonezawa A.; Masuda, S.; Yokoo, S.; Katsura, T.; Inui, K.; Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxic extrusion family). J. Pharmacol. Exp. Ther., 2006, 319, 879-886.
4. Zhang. S.; Lovejoy, K.S.; Shima, J.E.; Lagpacan, L.L.; Shu, Y.; Lapuk, A.; Chen, Y.; Komori, T.; Gray, J.W.; Chen, X.; Lippard, S.J.; Giacomini, K.M.; Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res., 2006, 66, 8847-8857.
5. Zhou, B; Gitschier, J.; hCTR1: A human gene for copper uptake identified by complementation in yeast. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 7481-7486.
6. Loo, T.W.; Clarke, D.M.; Molecular dissection of the human multidrug resistance P-glycoprotein, Biochem. Cell Biol., 1999, 77, 11-23.
7. Bakos, E.; Hegedus, T.; Hollo, Z.; Welker, E.; Tusnady, G.E.; Zaman, G.J.R.; Flens, M.J.; Varadi, A.; Sarkadi, B.; Membrane topology and glycosylation of the human multidrug resistanceassociated protein, J. Biol. Chem., 1996, 271, 12322-12326.
8. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D.; A multidrug resistance transporter from human MCF-7 breast cancer cells, Proc. Natl. Acad. Sci., 1998, 95, 15665-15670.
9. Bates, S.E.; Robey, R.; Miyake, K.; Rao, K.; Ross, D.D.; Litman, T.; The role of half-transporters in multidrugresistence, J. Bioenerg. Biomembr., 2001, 33, 503-511.
10. Higgins, C.F.; Gottesman, M.M.; Is the multidrug transporter a flippase? Trends Biochem. Sci., 1992, 17, 18-21.
11. Cordon-Cardo, C.; O'Brien, J.P.; Casals, D.; Rittman-Grauer, L.; Biedler, J.L.; Melamed, M.R.; Bertino, J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodbrain barrier sites, Proc. Natl. Acad. Sci. USA, 1989, 86, 695-698.
12. Schinkel, A.H.; Smit, J.J.M.; van Tellingen, O.; Beijnen, J.H.; Wagenaar, E.; van Deemter, L.; Mol C.A.A.M.; van der Valk, M.A.; Robanus-Maandag, E.C.; Riele, H.P.J.; Berns, A.J.M.; Borst, P.; Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 1994, 77, 491-502.
13. Saito, T.; Zhang, Z.J.; Ohtsubo, T.; Noda, I.; Shibamori, Y.; Yamamoto, T.; Saito, H.; Homozygous disruption of the mdr1a Pglycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs,. Acta Otolaryngol., 2001, 121, 735-742.
14. Fricker, G.; Miller D.S.; Modulation of drug transporters at the blood-brain barrier. Pharmacology, 2004, 70, 169-176.
15. Lankas, G.R.; Cartwright, M.E.; Umbenhauer, D.; P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectininduced neurotoxicity. Toxicol. Appl. Pharmacol., 1997, 143, 357-365.
16. Schinkel, A.H.; Smit, J.J.M.; van Tellingen, O.; Beijnen, J.H.; Wagenaar, E.; van Deemter, L.; Mol C.A.A.M.; van der Valk, M.A.; Robanus-Maandag, E.C.; Riele, H.P.J.; Berns, A.J.M.; Borst, P.; Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 1994, 77, 491-502.
17. Leslie, E.M.; Deeley, R.G.; Cole, S.P.C.; Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol., 2005, 204, 216-237.
18. Bendayan, R.; Lee, G.; Bendayan, M.; Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc. Res. Tech., 2002, 57, 365-380.
19. Lee, G.; Schlichter, L.; Bendayan, M.; Bendayan, R.; Functional expression of P-glycoprotein in rat brain microglia. J. Pharmacol. Exp. Ther., 2001, 299, 204-212. (Pubitemid 32905136)
20. Ronaldson, P.T.; Bendayan, M.; Gingras, D.; Piquette-Miller, M.; Bendayan, R.; Cellular localization and functional expression of Pglycoprotein in rat astrocyte cultures. J. Neurochem., 2004, 89, 788-800.
21. Olsson, Y.; Vascular permeability in the peripheral nervous system. In: Peripheral neuropathy. Dyck, P.J.; Thomas, P.K.; Lambert, E.H.; Eds. Saunders Philadelphia, 1975, pp. 190-200.
22. Arvidson, B.; Tjalve, H.; Distribution of 109Cd in the nervous system of rats after intravenous injection. J. Environ. Pathol. Toxicol. Oncol., 1985, 6, 233-240.
23. Saito, T.; Zhang, Z.J.; Shibamori, Y.; Ohtsubo, T.; Noda, I.; Yamamoto, T.; Saito, H.; P-glycoprotein expression in capillary endothelial cells of the 7th and 8th nerves of guinea pig in relation to blood-nerve.barrier sites. Neurosci. Lett., 1997, 232, 41-44. (Pubitemid 27382115)
24. Saito, T.; Zhang, Z.J.; Ohtsubo, T.; Noda, I., Tokuriki, M.; Shibamori, Y.; Yamamoto, T.; Saito, H.; Inhibitory effect of cyclosporin A on p-glycoprotein function in peripheral nerves of mice treated with doxorubicin and vinblastine. Acta Otolaryngol., 2004, 124, 313-317.
25. Balayssac, D.; Cayre, A.; Authier, N.; Bourdu, S.; Penault-Llorca, F.; Gillet, J. P.; Maublant, J.; Eschalier, A.; Coudore, F.; Patterns of P-glycoprotein activity in the nervous system during vincristineinducedneuropathy in rats. J. Peripher. Nerv. Syst., 2005, 10, 301-310.
26. Beck, J.F.; Brugger, D.; Brischwein K.; Liu, C.; Bader, P.; Niethammer, D.; Gekeler, V.; Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lynphoblastic leukemias. Jpn. J. Cancer Res., 2001, 92, 896-903.
27. Balayssac, D.; Cayre, A.; Authier, N.; Ling, B.; Maublant, J.; Eschalier, A.; Penault-Llorca, F.; Coudore, F.; Involvment of the multidrug resistance transporters in cisplatin-induced neuropathy in rats. Comparison with the chronic constriction injury model and monoarthritic rats. Eur. J. Pharmacol., 2006, 544, 49-57.
28. Croop, J.M.; Raymond, M.; Haber, D.; Devault, A.; Arceci, R.J.; Gros, P.; Housman, D.E.; The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell. Biol., 1989, 9, 1346-50.
29. Biegel, D.; Spencer D.D; Pachter, J.S.; Isolation and culture of human brain microvessel endothelial cells for the study of bloodbrain barrier properties in vitro. Brain Res., 1995, 692, 183-189.
30. Beaulieu, E.; Demeule, M.; Ghitescu, L.; Beliveau, R,; Pglycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem. J., 1997, 326, 539-544.
31. van der Sandt, I.C.; Vos, C.M.; Nabulsi, L. ; Blom-Roosemalen, M.C.; Voorwinden, H.H.; de Boer A.G.; Breimer, D.D.; Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS, 2001, 15, 483-491.
32. Megard, I.; Garrigues, A.; Orlowski, S.; Jorajuria, S. ; Clayette, P.; Ezan E.; Mabondzo, A.; A co-culture-based model of human blood-brain barrier: Application to active transport of indinavir and in vivo-in vitro correlation. Brain Res., 2002, 927, 153-167.
33. Dagenais, C.; Zong, J.; Ducharme J,; Pollack, G.M.; Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm. Res., 2001, 18, 957-963.
34. Kerb, R.; Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett., 2006, 234, 4-33.
35. Ieiri, I.; Takane, H.; Otsubo K.; The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin. Pharmacokinet., 2004, 43, 553-576.
36. Sissung, T.M.; Mross, K.; Steinberg, S.M.; Behringer, D.; Figga, W.D.; Sparreboom, A.; Mielked, S.; Association of ABCB1 Genotypes with Paclitaxel-mediated Peripheral Neuropathy and Neutropenia. Eur. J. Cancer, 2006, 42, 2893-2896.
37. Daugaard, G.K.; Petrera, J.; Trojaborg W.; Electrophysiological study of the peripheral and central neurotoxic effect of cisplatin. Acta. Neurol. Scand., 1987, 76, 86-93
38. Thompson, S.W.; Davis, L.E.; Kornfeld, M.; Hilgers, R.D.; Standefer, J.C.; Cisplatin neuropathy: Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer, 1984, 54, 1269-1275.
39. Krarup-Hansen, A.; Helweg-Larsen, S.; Schmalbruch, H.; Rørth, M.; Krarup, C.; Neuronal involvement in cisplatin neuropathy: Prospective clinical and neurophysiological studies. Brain, 2007, 130, 1076-1088.
40. Roelofs, R.I.; Hrushesky, W.; Rogin, J.; Rosenberg, L.; Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology, 1984, 34, 934-938.
41. Krarup-Hansen, A.; Rietz, B.; Krarup, C.; Heydorn, K.; Rørth, M.; Schmalbruch, H.; Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: An autopsy study. Neuropathol. Appl. Neurobiol., 1999, 25, 29-40.
42. Cavaletti, G.; Tredici, G.; Petruccioli, M.G.; Dondé, E.; Tredici, P.; Marmiroli. P.; Minoia, C.; Ronchi, A.; Bayssas, M.; Etienne, G.G.; Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur. J. Cancer, 2001, 37, 2457-2463.
43. Holmes, J.; Stanko, J.; Varchenko, M.; Ding, H.; Madden, V.J.; Bagnell, C.R.; Wyrick, S.D.; Chaney, S.G.; Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol. Sci., 1998, 46, 342-351.
44. McKeage, M.J.; Hsu T.; Screnci, D.; Haddad, G.; Baguley, B.C.; Nuclear damage correlates with neurotoxicity induced by different platinum drugs. Br. J. Cancer, 2001, 85, 1219-1225.
45. Jamieson, S.M.; Liu, J.; Connor, B.; McKeage, M.J.; Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother. Pharmacol., 2005, 56, 391-399.
46. Cavaletti, G.; Tredici, G.; Marmiroli, P.; Petruccioli, M.G.; Barajon, I.; Fabbrica, D.; Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol., 1992, 84, 364-371.
47. Cavaletti, G.; Fabbrica, D.; Minoia, C.; Frattola, L.; Tredici, G.; Carboplatin toxic effects on the peripheral nervous system of the rat. Ann. Oncol., 1998, 9, 443-447.
48. Eastman A.; Reevaluation of interaction of cis-dichloro (ethylenediamine)platinum(II) with DNA. Biochemistry, 1986, 25, 3912-3915.
49. Kartalou, M.; Essigmann, J.M.; Mechanisms of resistance to cisplatin. Mutat. Res., 2001, 478, 23-43.
50. McDonald, E.S.; Randon, K.R.; Knight, A.; Windebank, A.J.; Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity. Neurobiol. Dis., 2005, 18, 305-313.
51. Meijer, C.; de Vries, E.G.; Marmiroli, P.; Tredici, G.; Frattola, L.; Cavaletti, G.; Cisplatin induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology, 1999, 20, 883-887.
52. Ta, L.E.; Espeset, L.; Podratz, J.; Windebank, A.J.; Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology, 2006, 27, 992-1002.
53. Dzagnidze, A.; Katsarava, Z.; Makhalova, J.; Liedert, B.; Yoon, M.S.; Kaube, H.; Limmroth, V.; Thomale, J.; Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J. Neurosci., 2007, 27, 9451-9457.
54. Masuyama, H.; Suwaki, N.; Tateishi, Y.; Nakatsukasa, H.; Segawa, T.; Hiramatsu, Y.; The pregnane X receptor regulates gene expression in a ligand- and promoter- selective fashion. Mol. Endocrinol., 2005, 19, 1170-1180.
55. Xu, C.; Li, C.Y.; Kong, A.N.; Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res., 2005, 28, 249-268.
56. Ohga, T.; Uchiumi, T.; Makino, Y.; Koike, K.; Wada, M.; Kuwano, M.; Kohno, K.; Direct involvement of the Y-box binding protein YB-1 in the genotoxic stress-induced activation of the human multidrug resistance gene. J. Biol. Chem., 1998, 273, 5997-6000.
57. 4 and structurally related conjugates. J. Biol. Chem., 1994, 269, 27807-27810.
58. Müller, M.; Meijer, C.; Zaman, G.J.R.; Borst, P.; Scheper, R.J.; Mulder, N.H.; de Vries E.G.E.; Jansen, P.L.M.; Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA, 1994, 91, 13033-13037.
59. Evers, R.; Zaman, G.J.R.; van Deemter, L.; Jansen, H.; Calafat, J.; Oomen, L.C.J.M.; Oude Elferink, R.P.J.; Borst P.; Schinkel, A.H.; Basolateral localization and export activity of the human multidrug resistance-associated protein (MRP) in polarized pig kidney cells. J. Clin. Invest., 1996, 97, 1211-1218.
60. Loe, D.W.; Almquist,; K.C.; Cole S.P.C.; Deeley, R.G.; ATPdependent 17β-estradiol 17-(β-d-glucuronide) transport by multidrug resistance protein (MRP). J. Biol. Chem. 1996, 271, 9683-9689.
61. Rappa, G.; Lorico, A.; Flavell R.A.; Sartorelli, A.C.; Evidence that the multidrug resistance protein (MRP) functions as a cotransporter of glutathione and natural product toxins. Cancer Res., 1997, 57, 5232-5237.
62. Loe, D.W.; Deeley R.G.; Cole, S.P.C.; Characterization of vincristine transport by the Mr 190,000 multidrug resistance protein (MRP): Evidence for cotransport with reduced glutathione. Cancer Res., 1998, 58, 5130-5136.
63. Zaman, G.J.R.; Lankelma, J.; van Tellingen, O.; Beijnen, J.H.; Dekker, H.; Paulusma, C.; Oude Elferink R.P.J.; Baas F.; Borst, P.; Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA 1995, 92, 690-7694.
64. Kruh, G.D.; Zeng, H.; Rea, P.A.; Liu, G.; Chen, Z.; Lee, K.; Belinsky, M-G.; MRP Subfamily Transporters and Resistance to Anticancer Agents. J. Bioenerg. Biomembr., 2001, 33, 493-501.
65. Cui, Y.; König, J.; Buchholz, J.K.; Spring, H.; Leier, I.; Keppler, D.; Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol., 1999, 55, 929-937.
66. Koike, K.; Kawabe, T.; Tanaka, T.; Toh, S.; Uchiumi, T. ; Wada, M.; Akiyama, S.; Ono, M.;, Kuwano, M.; A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res., 1997, 57, 5475-5479.
67. Maher, J.M.; Slitt, A.L.; Cherrington, N.J.; Cheng, X.; Klaassen, C.D.; Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug. Metab. Dispos., 2005, 33, 947-955.
68. Nies, A.T.; Jedlitschky, G.; König, J.; Herold-Mende, C.; Steiner, H.H.; Schmitt, H.P.; Keppler, D.; Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1- ABCC6), in human brain. Neuroscience, 2004, 129, 349-360.
69. Miller, D.S.; Nobmann, S.N.; Gutmann, H.; Toeroek, M.; Drewe, J.; Fricker, G.; Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol., 2000, 58, 1357-1367.
70. Cherrington, N.J.; Hartley, D.P.; Li, N.; Johnson, D.R.; Klaassen, C.D.; Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J. Pharmacol. Exp. Ther., 2002, 300, 97-104.
71. Potschka, H.; Fedrowitz, M.; Löscher, W.; Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J. Pharmacol. Exp. Ther., 2003, 306, 124-131.
72. Cisternino, S.; Rousselle, C.; Lorico, A.; Rappa, G.; Scherrmann, J.M.; Apparent lack of Mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells. Pharm. Res., 2003, 20, 904-909.
73. Wijnholds, J.; de Lange, E.C.M.; Scheffer, G.L.; van den Berg, D.J.; Mol, C.A.A.M.; van der Valk, M.; Schinkel, A.H.; Scheper, R.J.; Breimer, D.D.; Borst, P.; Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the bloodcerebrospinal fluid barrier. J. Clin. Invest., 2000, 105, 279-285
74. Johnson, D.R.; Finch, R.A.; Lin, Z.P.; Zeiss, C.J.; Sartorelli, A.C.; The pharmacological phenotype of combined multidrug-resistance mdr1a/1b and mrp1-deficient mice. Cancer Res., 2001, 61, 1469-1476.
75. Lee, H.L.; Lee, K.M.; Son, S.J.; Hwang, S.H.; Cho, H.J.; Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. NeuroReport, 2004, 15, 2807-2811.
76. Sukhai, M.; Piquette-Miller, M.; Regulation of the multidrug resistance genes by stress signals. J. Pharm. Pharmacol. Sci., 2000, 3, 268-280.
77. Felix, R.A.; Barrand, M.A.; P-glycoprotein expression in rat brain endothelial cells: Evidence for regulation by transient oxidative stress. J. Neurochem., 2002, 80, 64-72.
78. Samimi, S.; Safaei, R.; Katano, K.; Holzer, A.K.; Rochdi, M.; Tomioka, M.; Goodman, M., Howell, S.B.; Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res., 2004, 10, 4661-4669.
79. Komatsu, M.; Sumizawa, T.; Mutoh, M.; Chen, Z.S.; Tarada, K.; Furukawa, T.; Yang, X.L.; Gao, H.; Miura, N.; Sugiyama, T.; Akiyama, S.; Copper transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res., 2000, 60, 1313-1316.
80. Nakayama, K.; Kanzaki, A.; Terada, K.; Mutoh, M.; Ogawa, K.; Sugiyama, Takenoshita, S.; Itoh, K.; Yaegashi, N.; Miyazaki, K.; Neamati, N.; Takebayashi, Y.; Prognostic value of the cutransporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin. Cancer Res., 2004, 10, 2804-2811.
81. Ohbu, M.; Ogawa, K.; Konno, S.; Kanzaki, A.; Terada, K.; Sugiyama, T.; Takebayashi, Y.; Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human gastric carcinoma. Cancer Lett., 2003, 189, 33-38. (Pubitemid 35351517)
82. Ishida, S.; Lee, J.; Thiele, D.J.; Herskowitz, I.; Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. USA, 2002, 99, 14298-14302.
83. Lin, X.; Okuda, T.; Holzer, A.; Howell, S.B.; The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol. Pharmacol., 2002, 62, 1154-1159.
84. Song, I.S.; Savaraj, N.; Siddik, Z.H.; Liu, P.; Wei, Y.; Wu, C.J.; Kuo, M.T.; Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin- resistant cells. Mol. Cancer Ther., 2004, 3, 1543-1549.
85. Holzer, A.K.; Manorek, G.H.; Howell, S.B.; Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol., 2006, 70, 1390-1394.
86. Lee, J.; Prohaska, J.R.; Dagenais, S.L.; Glover, T.W.; Thiele, D.J.; Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene, 2000, 254, 87-96.
87. Kuo, Y.M.; Zhou, B.; Cosco, D.; Gitschier, J.; The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc. Natl. Acad. Sci. USA, 2001, 98, 6836-6841.
88. Gregg, R.W.; Molepo, J.M.; Monpetit, V.J.; Mikael, N.Z.; Redmond, D.; Gadia, M.; Stewart, D.J.; Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J. Clin. Oncol., 1992, 10, 795-803.
89. Screnci, D.; McKeage, M.J.; Galettis, P.; Hambley, T.W.; Palmer, B.D.; Baguley, B.C.; Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br. J. Cancer, 2000, 82, 966-972.
90. Cavaletti, G.; Tredici, G.; Pizzini, G.; Minoia A.; Tissue platinum concentrations and cisplatin schedules. Lancet, 1990, 336, 1003.
91. Screnci, D.; Er, H.M.; Hambley, T.W.; Galettis, P.; Brouwer, W.; McKeage, M.J.; Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br. J. Cancer, 1997, 76, 502-510.
92. Lee, J.; Petris, M.J.; Thiele, D.J.; Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system. J. Biol. Chem., 2002, 277, 40253-40259.
93. Holzer, A.K.; Varki, N.M.; Le Q.T.; Gibson, M.A.; Naredi, P.; Howell, S.B.; Expression of the human copper influx transporter 1 in normal and malignant human tissues. J. Histochem. Cytochem., 2006, 54, 1041-1049.
94. Liu, J.J.; Jamieson, S.M.F.; Subramaniam, J.; Ip, V.; Jong, N.N.; Mercer, J.F.B.; McKeage, M.J.; Neuronal expression of copper transporter 1 in rat dorsal root ganglia: Association with platinum neurotoxicity. Cancer Chemother. Pharmacol., 2009, 64, 847-856.
95. Holzer, A.K.; Manorek, G.H.; Howell, S.B.; Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006, 70, 1390-1394.
96. Holzer, A.K.; Katano, K.; Klomp, L.W.; Howell, S.B.; Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin. Cancer Res., 2004, 10, 6744-6749. (Pubitemid 39346572)
97. Holzer, A.K.; Howell, S.B.; The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res., 2006, 66, 10944-10952.
98. Waggoner, D.J.; Bartnikas, T.B.; Gitlin, J.D.; The role of copper in neurodegenerative disease. Neurobiol. Dis., 1999, 6, 221-230.
99. Koepsell, H.; Lips, K.; Volk, C.; Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res., 2007, 24, 1227-1251.
100. Wu, X.; Prasad, P.D.; Leibach, F.H.; Ganapathy, V.; cDNA sequence, transport function and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem. Biophys. Res. Commun., 1998, 246, 589-595.
101. Enomoto, A.; Kimura, H.; Chairoungdua, A.; Shigeta, Y.; Jutabha, P.; Cha, S.H.; Hosoyamada, M.; Takeda, M.; Sekine, T.; Igarashi, T.; Matsuo, H.; Kikuchi, Y.; Oda, T.; Ichida, K.; Hosoya, T.; Shimokata, K.; Niwa, T.; Kanai, Y.; Endou, H.; Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature, 2002, 417, 447-452.
102. Sweet, D.H.; Bush, K.T.; Nigam, S.K.; The organic anion transporter family: From physiology to ontogeny and the clinic. Am. J. Physiol. Renal Physiol., 2001, 281, F197-F205.
103. Gründemann, D.; Gorboulev, V.; Gambaryan, S.; Veyhl, M.; Koepsell, H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature (Lond), 1994, 372, 549-552.
104. Gorboulev, V.; Ulzheimer, J.C.; Akhoundova, A.; Ulzheimer- Teuber, I.; Karbach, U.; Quester, S.; Baumann, C.; Lang, F.; Busch, A.E.; Koepsell, H.; Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell. Biol., 1997, 16, 871-881. (Pubitemid 27332696)
105. Zhang, L.; Dresser, M.J.; Gray, A.T.; Yost, S.C.; Terashita, S.; Giacomini, K.M.; Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol., 1997, 51, 913-921.
106. Okuda, M.; Saito, H.; Urakami, Y.; Takano, M.; Inui, K.; cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem. Biophys. Res. Commun., 1996, 224, 500-507.
107. Gründemann, D.; Babin-Ebell, J.; Martel, F.; Ording, N.; Schmidt, A.; Schömig, E.; Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells. J. Biol. Chem., 1997, 272, 10408-10413.
108. Busch, A.E.; Karbach, U.; Miska, D.; Gorboulev, V.; Akhoundova, A.; Volk, C.; Arndt, P.; Ulzheimer, J.C.; Sonders, M.S.; Baumann, C.; Waldegger, S.; Lang, F.; Koepsell, H.; Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine and memantine. Mol. Pharmacol., 1998, 54, 342-352.
109. Gründemann, D.; Schechinger, B.; Rappold, G.A.; Schömig, E.; Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat. Neurosci., 1998, 1, 349-351.
110. Verhaagh, S.; Schweifer, N.; Barlow, D.P.; Zwart, R.; Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics, 1999, 55, 209-218.
111. Kekuda, R.; Prasad, P.D.; Wu, X.; Wang, H.; Fei, Y.; Leibach, F.H.; Ganapathy, V.; Cloning and functional characterization of a potential-sensitive polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J. Biol. Chem., 1998, 273, 15971-15979.
112. Wu, X.; Kekuda, R.; Huang, W.; Fei, Y.; Leibach, F.H.; Chen, J.; Conway, S.J.; Ganapathy, V.; Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J. Biol. Chem., 1998, 273, 32776-32786.
113. Inazu, M.; Takeda, H.; Matsumiya, T.; Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes. J. Neurochem., 2003, 84, 43-52.
114. Rajan, P.D.; Kekuda, R.; Chancy, C.D.; Huang, W.; Ganapathy, V.; Smith, S.B.; Expression of the extraneuronal monoamine transporter in RPE and neural retina. Curr. Eye Res., 2000, 20, 195-204.
115. Ciarimboli, G.; Ludwig, T.; Lang, D.; Pavenstädt, H.; Koepsell, H.; Piechota, H.J.; Haier, J.; Jaehde, U.; Zisowsky, J.; Schlatter, E.; Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol., 2005, 167, 1477-1484.
116. Morisaki, T.; Matsuzaki, T.; Yokoo, K.; Kusumoto, M.; Iwata, K.; Hamada, A.; Saito, H.; Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats. Pharm. Res., 2008, 25, 2526-2533.
117. Aleksunes, L.M.; Augustine, L.M.; Scheffer, G.L.; Cherrington, N.J.; Manautou, J.E.; Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology, 2008, 250, 82-88.
118. Ciarimboli, G.; Deuster, D.; Knief, A.; Sperling, M.; Holtkamp, M.; Edemir, B.; Pavenstädt, H.; Lanvers-Kaminsky, C.; Am Zehnhoff-Dinnesen, A.; Schinkel, A.H.; Koepsell, H.; Jürgens, H.; Schlatter, E.; Organic Cation Transporter 2 Mediates Cisplatin- Induced Oto- and Nephrotoxicity and Is a Target for Protective Interventions. Am. J. Pathol., 2010, 176, 1169-1180.
119. Quasthoff, S; Hartung, H.P.; Chemotherapy-induced peripheral neuropathy. J Neurol., 2002, 249, 9-17.
120. Cavaletti, G; Nicolini, G.; Marmiroli, P.; Neurotoxic effects of antineoplastic drugs: The lesson of pre-clinical studies. Front. Biosci., 2008, 13, 3506-3524.
121. Hamers, F.P.T.; Gerritsen, van Der Hoop, R.; Traber, J.; Neijt, J.P., Jannekens F.G.I.; Gispens, W.H.; The calcium antagonist nimodipine in cisplatin induced neuropathy in the rat. Eur. J. Pharmacol., 1990, 183, 1710-1711.
122. Cassidy, J.; Paul, J.; Soukop, M.; Habeshaw, T.; Reed, N.S.; Parkin, D.; Kaye, S.B.; Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol. 1998, 41,161-166.
123. Carozzi, V.A.; Canta, A.; Oggioni, N.; Ceresa, C.; Marmiroli, P.;.Kovalinka, J.; Zoia, C.; Bossi, M.; Ferrarese, C.; Tredici, G.; Cavaletti, G.; Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system. J. Anat., 2008, 213, 539-546.
124. Carozzi, V.A.; Chiorazzi, A.; Canta, A.; Lapidus, R.G.; Slusher, B.S.; Wozniak, K.M.; Cavaletti, G.; Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox. Res., 2010, 17, 380-391.
125. Xie, R.; Hammarlund-Udenaes, M.; de Boer, A.G.; de Lange, EC.; The role of P-glycoprotein in blood-brain barrier transport of morphine: Transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br. J. Pharmacol., 1999, 128, 563-568.
126. Uhr, M.; Grauer, M.T.; Holsboer, F.; Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1a) P-glycoprotein gene disruption. Biol. Psychiatry, 2003, 54, 840-846.
127. Tishler, D.M.; Weinberg, K.I.; Hinton, D.R.; Barbaro, N.; Annett, G.M.; Raffel, C.; MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia, 1995, 36, 1-6.
128. Dallel, R.; Voisin, D.; Towards a pain treatment based on the identification of the pain-generating mechanisms? Eur. Neurol., 2001, 45, 126-132.
129. Letrent, S.P.; Pollack, G.M.; Brouwer, K.R.; Brouwer, K.L.; Effects of a potent and specific P-glycoprotein inhibitor on the bloodbrain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab. Dispos., 1999, 27, 827-834.
130. Lötsch, J.; Schmidt, R.; Vetter, G.; Schmidt, H.; Niederberger, E.; Geisslinger, G.; Tegeder, I.; Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J. Neurochem., 2002, 83, 241-248.
131. Thomas, H.; Coley, H.M.; Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting pglycoprotein. Cancer Control., 2003, 10, 159-165.
132. van Zuylen, L.; Sparreboom, A.; van der Gaast, A.; van der Burg, M.E.; van Beurden, V.; Bol, C.J.; Woestenborghs, R.; Palmer, P.A.; Verweij, J.; The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin. Cancer Res., 2000, 6, 1365-1371.
133. Balayssac, D.; Cayre, A.; Ling, B.; Maublant, J.; Penault-Llorca, F.; Eschalier, A.; Coudoré, F.; Authier, N.; Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatininduced neuropathy. Neurosci Lett., 2009, 465, 108-112.